Literature DB >> 4064559

The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria).

R W Watts, N Veall, P Purkiss, M A Mansell, E F Haywood.   

Abstract

We have measured glomerular filtration rate (GFR), extracellular fluid volume (ECF), oxalate distribution volume (OxDV), plasma oxalate concentration (POx.), plasma total clearance of oxalate (PCOx.), oxalate metabolic pool size [(OxDV) X (POx.)], renal clearance of oxalate (RCOx.), oxalate excretion, tissue clearance of oxalate (TCOx.) and tissue oxalate accumulation rate [(TOx.A) = (TCOx.) X (POx.)] in three patients with type I primary hyperoxaluria (hyperoxaluria with hyperglycollic aciduria) when they were taking pyridoxine and after discontinuation of the vitamin. Seven days after stopping pyridoxine the plasma oxalate concentration, oxalate metabolic pool size and the urinary excretion of oxalate had all increased between seven- and eight-fold in two of the patients. The third patient showed no changes on stopping pyridoxine. These results support the view that pyridoxine acts by reducing oxalate biosynthesis in some patients with type I primary hyperoxaluria. The possible biochemical basis for this effect is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064559     DOI: 10.1042/cs0690087

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

1.  What treatment do you advise for a small child with hyperoxaluria presenting with renal calculi?

Authors:  R W Watts
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

2.  A rare twist to a common problem.

Authors:  L H Smith
Journal:  West J Med       Date:  1996-01

Review 3.  Primary and secondary hyperoxaluria: Understanding the enigma.

Authors:  Bhavna Bhasin; Hatice Melda Ürekli; Mohamed G Atta
Journal:  World J Nephrol       Date:  2015-05-06

4.  Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Authors:  Heike Hoyer-Kuhn; Sina Kohbrok; Ruth Volland; Jeremy Franklin; Barbara Hero; Bodo B Beck; Bernd Hoppe
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-02       Impact factor: 8.237

5.  Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant.

Authors:  E C Lorenz; J C Lieske; B M Seide; A M Meek; J B Olson; E J Bergstralh; D S Milliner
Journal:  Am J Transplant       Date:  2014-05-02       Impact factor: 8.086

6.  [Type I oxalosis in childhood--studies within the scope of terminal renal failure in the child].

Authors:  M Frosch; E Kuwertz-Bröking; M Bulla; D B von Bassewitz; D B Leusmann
Journal:  Klin Wochenschr       Date:  1989-11-17

Review 7.  Update on oxalate crystal disease.

Authors:  Elizabeth C Lorenz; Clement J Michet; Dawn S Milliner; John C Lieske
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

8.  Primary hyperoxaluria.

Authors:  Jérôme Harambat; Sonia Fargue; Justine Bacchetta; Cécile Acquaviva; Pierre Cochat
Journal:  Int J Nephrol       Date:  2011-06-16

Review 9.  Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I.

Authors:  Angel L Pey; Armando Albert; Eduardo Salido
Journal:  Biomed Res Int       Date:  2013-07-16       Impact factor: 3.411

Review 10.  Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.

Authors:  Thomas A Forbes; Bob D Brown; Chengjung Lai
Journal:  Br J Clin Pharmacol       Date:  2021-06-11       Impact factor: 3.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.